ACOR Financial Facts
Total other expense (net): -4.54MNet loss per share-basic (earnings per share): -0.28
See Full Income Statement
Other current assets: 4.86M
Property and equipment, net of accumulated depreciation: 35.78M
See Full Balance Sheet
Acorda Therapeutics, Inc. (ACOR) Earnings
|
Expand Research on ACOR
Next EPS Date | N/A | EPS Growth Rate | -139.7% *Last Qtr. |
---|---|---|---|
Average EPS % Beat Rate | -188.2% | Revenue Growth Rate | +63.1% *Last Qtr. |
Average % Move 1-Wk after EPS | -8.4% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
5/6/21 | Q121 | -$2.46 | -$2.54 | +$0.08 | $28.86M | $22.15M | N/A | Details | |||
3/9/22 | Q421 | -$0.67 | N/A | N/A | $36.97M | $31.01M | N/A | Details | |||
8/5/21 | Q221 | -$1.87 | -$2.09 | +$0.22 | $31.78M | $29.94M | N/A | Details | |||
11/9/21 | Q321 | -$1.43 | -$1.56 | +$0.13 | $31.45M | $30.57M | N/A | Details | |||
3/4/21 | Q420 | -$2.50 | -$1.48 | -$1.02 | $38.16M | $34M | N/A | Details | |||
8/1/19 | Q219 | -$0.58 | -$1.06 | +$0.48 | $50.05M | $28.82M | = | Details | |||
5/2/19 | Q119 | -$0.56 | -$0.94 | +$0.38 | $44.14M | $33.04M | = | Details | |||
2/14/19 | Q418 | $0.45 | -$0.63 | +$1.08 | $69.2M | $48.1M | = | Details |